Navigation Links
Haemacure Update on Proposed Collaboration and Bridge Financing
Date:5/22/2009

In such event, a portion of the loan will be converted into another type of Haemacure security, as agreed to at that time by Angiotech and Haemacure. Angiotech has an option to advance to Haemacure on the day immediately preceding the closing of such equity financing all draw-downs that have not previously been advanced to Haemacure, to the maximum amount of US$2.5 million. In the event of the conversion of the loan into shares, Angiotech will be entitled to one seat on Haemacure's Board of Directors. In the event that there is no such equity financing, the principal amount of the loan and all accrued interest will be payable by Haemacure upon the loan's maturity.

Upon the closing, if any, of the equity financing by Haemacure, it will issue a warrant to Angiotech exercisable for the same type of security as that issued by Haemacure in the equity financing. The warrant will: (i) be exercisable for a number of Haemacure securities arrived at by dividing 100% of the loan amount plus accrued interest by the issue price of the equity financing; (ii) have an exercise price equal to the issue price of the equity financing; and (iii) have a term equal to the term of warrants, if any, issued in the equity financing. In the event that no warrants are issued by Haemacure in the equity financing, the warrant issued to Angiotech will have a term of five years from the date of closing of the equity financing.

Haemacure and Angiotech are also preparing definitive collaboration agreements under which Angiotech will have certain license and distribution rights to Haemacure's fibrin sealant and thrombin. It is expected that the collaboration agreements will be signed on or about June 1, 2009.

Completion of the transaction is conditional on standard closing conditions, including final negotiation and execution of loan and security documentation and the related collaboration agreements. Haemacure can give no assurance that the various closing conditions will be
'/>"/>

SOURCE Haemacure Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Signs Term Sheet for Proposed Collaboration and Bridge Financing
2. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
3. Haemacure Restructures - Seeks Financing or Sale of the Company
4. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
5. Haemacure Announces Fiscal 2008 Results
6. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
7. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
8. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
9. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
10. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
11. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- For wounded U.S. servicemen and women ... D.C., the holidays can be a particularly difficult time. ... rely more than ever on the healing power of ... home just got easier for Walter Reed patients as ... will provide hundreds of minutes of holiday talk time ...
(Date:12/16/2009)... deadly, attack is long-term goal, researchers say , , ... a tool to predict whether a patient will suffer ... stroke. , "This is an important new tool because ... stroke soon after a first stroke are more likely ... of Massachusetts General Hospital and Harvard Medical School, said ...
(Date:12/16/2009)... advance that could help ease health and environmental concerns ... of technology for changing the behavior of nanoparticles in ... the environment. Their study was published in ACS, journal ... from the UK Centre for Ecology and Hydrology and ... production of nanoparticles particles less than 1/1000th the ...
(Date:12/16/2009)... Cost-Effective Care , ... Washington, D.C. (Vocus) December 16, ... ways to rein in runaway costs while providing care to all ... the ongoing discussion includes how to ensure patients equal access to ... (MDs) or osteopathy (DOs). In both the House and Senate ...
(Date:12/16/2009)... Substance Specific Neurological Stress Reduction Therapy or NSRTSM is found ... chronic conditions such as allergies, asthma, migraines, chronic fatigue and ... practices throughout the country are using this holistic therapy including ... ... Minneapolis, MN (Vocus) December 14, 2009 ...
Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Behavior modification could ease concerns about nanoparticles 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5
... 29 categories of awards in the 2007 Association TRENDS ... Monthly Professional Society Magazine as well as the category ... will be honored at the Salute to Association Excellence ... JBS is the official publication of the Society for ...
... Technology,Inc. (Nasdaq: ALGN ), the inventor of ... and brackets, announced today that the,Company will report ... on,Tuesday, January 29, 2008, after the close of ... and First Call and will be available on,the ...
... (Nasdaq:,CRYO), a medical device company focused on the ... a European study of atrial,fibrillation patients treated with ... was to evaluate the role of atrial flutter ... of an ablation,strategy focused on isolating the pulmonary ...
... Calif., Jan. 4 DaVita Inc. (NYSE:,DVA) announced ... (,SKI,),have formed a wide-ranging partnership to provide dialysis ... disease education and research,in the greater Phoenix area. ... centers and programs designed to provide patients with,access ...
... Jan. 2 Roxane Laboratories, Inc.,announced today ... Application (ANDA),for Granisetron Hydrochloride Tablets, 1mg by ... is available in Unit Dose Blisters and ... pharmacies nationwide., (Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO ...
... deal and free unique support channels, OWINGS MILLS, ... today announced that the Company is offering a special ... centers. Medifast is,offering Pure Weight Loss clients $55 Off ... at http://www.puremedifast.com or by calling 800-692-1791., ...
Other Medicine News:Health News:Align Technology to Announce Fourth Quarter and 2007 Year End Financial Results on January 29, 2008 2Health News:Align Technology to Announce Fourth Quarter and 2007 Year End Financial Results on January 29, 2008 3Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 2Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 3Health News:Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 3
(Date:12/16/2009)... Scientists at,deCODE genetics, Inc. (Nasdaq: DCGN ... a version of a common single-letter variant in ... major impact on susceptibility to type 2,diabetes (T2D). ... only large, but unusual:,if an individual inherits it ... by more than 30% compared to those who ...
(Date:12/16/2009)... Wis., Dec. 16 EuroPharma, Inc. ... for the use of super absorbency BCM-95® ... EuroPharma formulations. The exclusive distribution territory ... health food store channel and professional channel, ... and clinics. BCM-95® is a highly ...
(Date:12/16/2009)... Inc. today announced the treatment of the first ... adhesive product, TissuGlu®. Initiation of the study marks ... the lead product toward clinical practice. ,, ... study to investigate the safety of TissuGlu and ... in abdominoplasty, or "tummy tuck," surgeries. The study ...
Breaking Medicine Technology:deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3Rare genetic disease successfully reversed using stem cell transplantation 9972 1Rare genetic disease successfully reversed using stem cell transplantation 9972 2Rare genetic disease successfully reversed using stem cell transplantation 9972 3Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 1Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 2Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 3Trust for Americas Health Applauds HHS Announcement of Prevention and Wellness Fund of the American Recovery and Reinvestment Act 57556 1Trust for Americas Health Applauds HHS Announcement of Prevention and Wellness Fund of the American Recovery and Reinvestment Act 57556 2
... HARBIN, China, May 4 /PRNewswire-Asia-FirstCall/ -- China ... Medical" or "the Company") (Nasdaq: CSKI ), ... in the People,s Republic of China ("PRC"), today announced ... Sudden Cardiac Death (SCD) Early Examination Kit has been ...
... Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical,company Pharmaxis (ASX: PXS; ... positive,results of its recently completed international Phase III trial ... represents one of,the largest clinical trials conducted in cystic ... of the trial was to assess whether Bronchitol,improves lung ...
Other Medicine Technology:China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit 2China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 2Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 4Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 5
NIDEK's US-1800 is an industry leader offering both combination pachymeter and ultrasound functionalities. The unit features and includes the latest IOL power calculation software, a touch screen pan...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
Steerable catheter that is ideal for mapping unusual anatomy...
... specifically designed for use with our CARTO ... NAVI-STAR catheter houses a Biosense Webster sensor ... real time, exact location points from within ... information. The NAVI-STAR electro-anatomical navigation catheter is ...
Medicine Products: